FI63568C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara i 7-staellning substituerade 8-aminometylisoflavonderivat - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara i 7-staellning substituerade 8-aminometylisoflavonderivat Download PDFInfo
- Publication number
- FI63568C FI63568C FI751272A FI751272A FI63568C FI 63568 C FI63568 C FI 63568C FI 751272 A FI751272 A FI 751272A FI 751272 A FI751272 A FI 751272A FI 63568 C FI63568 C FI 63568C
- Authority
- FI
- Finland
- Prior art keywords
- isoflavone
- isopropoxy
- general formula
- compounds
- solution
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 9
- 230000001225 therapeutic effect Effects 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 21
- -1 7-substituted 8-aminomethylisoflavone Chemical class 0.000 claims description 16
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 150000003335 secondary amines Chemical class 0.000 claims description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 2
- YLLSRADIWJBFIT-UHFFFAOYSA-N 8-(aminomethyl)-3-phenylchromen-4-one Chemical class NCC1=C2OC=C(C(=O)C2=CC=C1)C1=CC=CC=C1 YLLSRADIWJBFIT-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000001424 substituent group Chemical class 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 47
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 24
- 238000001816 cooling Methods 0.000 description 23
- 238000002844 melting Methods 0.000 description 22
- 230000008018 melting Effects 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 235000002639 sodium chloride Nutrition 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 238000009835 boiling Methods 0.000 description 18
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 17
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 13
- 235000008696 isoflavones Nutrition 0.000 description 13
- 239000011664 nicotinic acid Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 235000001968 nicotinic acid Nutrition 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- VTKOIVKQOOIMEJ-UHFFFAOYSA-N 8-(morpholin-4-ylmethyl)-3-phenyl-7-propan-2-yloxychromen-4-one Chemical compound CC(C)OC1=CC=C2C(=O)C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1 VTKOIVKQOOIMEJ-UHFFFAOYSA-N 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- QFOILJZOWCPCGC-UHFFFAOYSA-N 8-(chloromethyl)-3-phenyl-7-propan-2-yloxychromen-4-one Chemical compound ClCC=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 QFOILJZOWCPCGC-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 6
- 239000000155 melt Substances 0.000 description 6
- 229960003512 nicotinic acid Drugs 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- LEGMBEQCGGUNGX-UHFFFAOYSA-N 3-phenyl-7-propan-2-yloxy-8-(pyrrolidin-1-ylmethyl)chromen-4-one Chemical compound CC(C)OC1=CC=C2C(=O)C(=COC2=C1CN1CCCC1)C1=CC=CC=C1 LEGMBEQCGGUNGX-UHFFFAOYSA-N 0.000 description 5
- PINJIAAGOCZEHW-UHFFFAOYSA-N 3-phenyl-8-(piperidin-1-ylmethyl)-7-propan-2-yloxychromen-4-one Chemical compound CC(C)OC1=CC=C2C(=O)C(=COC2=C1CN1CCCCC1)C1=CC=CC=C1 PINJIAAGOCZEHW-UHFFFAOYSA-N 0.000 description 5
- RAULIAHRYVMDHP-UHFFFAOYSA-N 7-methoxy-8-(morpholin-4-ylmethyl)-3-phenylchromen-4-one Chemical compound COC1=CC=C2C(=O)C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1 RAULIAHRYVMDHP-UHFFFAOYSA-N 0.000 description 5
- BCULUQKZNIXWAH-UHFFFAOYSA-N CC(C)OC(C(C(C)NCCO)=C1OC=C2C3=CC=CC=C3)=CC=C1C2=O Chemical compound CC(C)OC(C(C(C)NCCO)=C1OC=C2C3=CC=CC=C3)=CC=C1C2=O BCULUQKZNIXWAH-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 3
- GIBWIWCQZADDCC-UHFFFAOYSA-N 7-hexadecoxy-8-(morpholin-4-ylmethyl)-3-phenylchromen-4-one Chemical compound CCCCCCCCCCCCCCCCOC1=CC=C2C(=O)C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1 GIBWIWCQZADDCC-UHFFFAOYSA-N 0.000 description 3
- LNSBUEBEDMIYIC-UHFFFAOYSA-N 8-(chloromethyl)-7-methoxy-3-phenylchromen-4-one Chemical compound ClCC=1C(OC)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 LNSBUEBEDMIYIC-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- FWWWREFFXDEYFG-UHFFFAOYSA-N 8-(chloromethyl)-7-hexadecoxy-3-phenylchromen-4-one Chemical compound CCCCCCCCCCCCCCCCOC1=CC=C2C(=O)C(=COC2=C1CCl)C1=CC=CC=C1 FWWWREFFXDEYFG-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- YBHVEVCAIMAIDP-UHFFFAOYSA-N CC1=C(C(=O)C2=C(O1)C(=C(C=C2)OC)N(C)CCO)C3=CC=CC=C3 Chemical compound CC1=C(C(=O)C2=C(O1)C(=C(C=C2)OC)N(C)CCO)C3=CC=CC=C3 YBHVEVCAIMAIDP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- KBFHWSOYEVGKBV-UHFFFAOYSA-N 4-[4-oxo-3-phenyl-8-(piperidin-1-ylmethyl)-7-propan-2-yloxychromen-2-yl]pyridine-3-carboxylic acid Chemical compound CC(C)OC1=C(C2=C(C=C1)C(=O)C(=C(O2)C3=C(C=NC=C3)C(=O)O)C4=CC=CC=C4)CN5CCCCC5 KBFHWSOYEVGKBV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GKGTXSJKLDFOQN-UHFFFAOYSA-N 7-hexadecoxy-3-phenylchromen-4-one Chemical compound C=1C(OCCCCCCCCCCCCCCCC)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 GKGTXSJKLDFOQN-UHFFFAOYSA-N 0.000 description 1
- ZLACZVOVAPXJCV-UHFFFAOYSA-N 7-hexadecoxy-8-(morpholin-4-ylmethyl)-3-phenylchromen-4-one hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCCCOC1=CC=C2C(=O)C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1 ZLACZVOVAPXJCV-UHFFFAOYSA-N 0.000 description 1
- YUDHPJZWEQJREQ-UHFFFAOYSA-N 7-methoxy-8-(morpholin-4-ylmethyl)-3-phenylchromen-4-one hydrochloride Chemical compound Cl.COC1=CC=C2C(=O)C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1 YUDHPJZWEQJREQ-UHFFFAOYSA-N 0.000 description 1
- IECSQLKWZBEUGA-UHFFFAOYSA-N 7-methoxyisoflavone Chemical compound C=1C(OC)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 IECSQLKWZBEUGA-UHFFFAOYSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- PIIPTBZMADEVBB-UHFFFAOYSA-N C(C)(C)OC1=CC=C2C(C(=COC2=C1N1CCOCC1)C1=CC=CC=C1)=O Chemical compound C(C)(C)OC1=CC=C2C(C(=COC2=C1N1CCOCC1)C1=CC=CC=C1)=O PIIPTBZMADEVBB-UHFFFAOYSA-N 0.000 description 1
- VJABGYMLWUEMAK-UHFFFAOYSA-N C(C1=CC=NC=C1)(=O)O.O1C=C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1 Chemical compound C(C1=CC=NC=C1)(=O)O.O1C=C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1 VJABGYMLWUEMAK-UHFFFAOYSA-N 0.000 description 1
- JCSUKZFMRRZJHT-UHFFFAOYSA-N C(C1=CN=CC=C1)(=O)O.C(C)(C)OC1=CC=C2C(C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1)=O Chemical compound C(C1=CN=CC=C1)(=O)O.C(C)(C)OC1=CC=C2C(C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1)=O JCSUKZFMRRZJHT-UHFFFAOYSA-N 0.000 description 1
- PSPKNYATEKIDBR-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)OC1=CC=C2C(C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1)=O.C(C)(C)OC1=CC=C2C(C(=COC2=C1CN1CCCC1)C1=CC=CC=C1)=O Chemical compound C(CCCCCCCCCCCCCCC)OC1=CC=C2C(C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1)=O.C(C)(C)OC1=CC=C2C(C(=COC2=C1CN1CCCC1)C1=CC=CC=C1)=O PSPKNYATEKIDBR-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- ZYGVWXMRKCGVKV-UHFFFAOYSA-N Cl.C(C)(C)OC1=CC=C2C(C(=COC2=C1CN1CCCC1)C1=CC=CC=C1)=O Chemical compound Cl.C(C)(C)OC1=CC=C2C(C(=COC2=C1CN1CCCC1)C1=CC=CC=C1)=O ZYGVWXMRKCGVKV-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- WWXGGEPDOVFJJH-UHFFFAOYSA-N O.Cl.CC(C)OC1=CC=C2C(=O)C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1 Chemical compound O.Cl.CC(C)OC1=CC=C2C(=O)C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1 WWXGGEPDOVFJJH-UHFFFAOYSA-N 0.000 description 1
- YTFLJYLPMMGHBS-UHFFFAOYSA-N O.Cl.O1C=C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1 Chemical compound O.Cl.O1C=C(C(=O)C2=CC=CC=C12)C1=CC=CC=C1 YTFLJYLPMMGHBS-UHFFFAOYSA-N 0.000 description 1
- QXRXXHZHMSFPAO-UHFFFAOYSA-N O1CCN(CC1)CC=1C=CC=C2C(C(=COC12)C1=CC=CC=C1)=O Chemical compound O1CCN(CC1)CC=1C=CC=C2C(C(=COC12)C1=CC=CC=C1)=O QXRXXHZHMSFPAO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- IJKJAWYATFQCQP-UHFFFAOYSA-N S(=O)(=O)(O)O.C(C)(C)OC1=CC=C2C(C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1)=O Chemical compound S(=O)(=O)(O)O.C(C)(C)OC1=CC=C2C(C(=COC2=C1CN1CCOCC1)C1=CC=CC=C1)=O IJKJAWYATFQCQP-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000007265 chloromethylation reaction Methods 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001729 effect on metabolism Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUCI1474A HU168753B (cs) | 1974-05-03 | 1974-05-03 | |
| HUCI001474 | 1974-05-03 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI751272A7 FI751272A7 (cs) | 1975-11-04 |
| FI63568B FI63568B (fi) | 1983-03-31 |
| FI63568C true FI63568C (fi) | 1983-07-11 |
Family
ID=10994519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI751272A FI63568C (fi) | 1974-05-03 | 1975-04-28 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara i 7-staellning substituerade 8-aminometylisoflavonderivat |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS6031831B2 (cs) |
| AR (1) | AR205818A1 (cs) |
| AT (1) | AT344167B (cs) |
| CH (1) | CH611289A5 (cs) |
| CS (1) | CS183794B2 (cs) |
| DD (1) | DD119587A1 (cs) |
| DE (1) | DE2518986A1 (cs) |
| DK (1) | DK191375A (cs) |
| FI (1) | FI63568C (cs) |
| FR (1) | FR2269340B1 (cs) |
| GB (1) | GB1482238A (cs) |
| HU (1) | HU168753B (cs) |
| IL (1) | IL47196A (cs) |
| NL (1) | NL7505214A (cs) |
| NO (2) | NO147485C (cs) |
| PL (1) | PL99666B1 (cs) |
| SU (1) | SU576938A3 (cs) |
| YU (1) | YU37335B (cs) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2516921A1 (fr) * | 1981-11-25 | 1983-05-27 | Lipha | Haloalkyl-8-4h-(1) benzopyran-4-ones, et procedes de preparation |
| DK0656786T3 (da) | 1992-05-19 | 2004-11-08 | Novogen Res Pty Ltd | Anvendelse af isoflavonphytoöstrogenekstrakter af soja eller klöver |
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| US6146668A (en) | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
| AUPP260798A0 (en) | 1998-03-26 | 1998-04-23 | Novogen Research Pty Ltd | Treatment of medical related conditions with isoflavone containing extracts of clover |
| AUPQ266199A0 (en) | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
| CN101429186B (zh) * | 2007-11-08 | 2012-11-21 | 中国医学科学院药物研究所 | 松属素外消旋体的拆分方法 |
-
1974
- 1974-05-03 HU HUCI1474A patent/HU168753B/hu unknown
-
1975
- 1975-01-01 AR AR258616A patent/AR205818A1/es active
- 1975-04-28 FI FI751272A patent/FI63568C/fi not_active IP Right Cessation
- 1975-04-29 DE DE19752518986 patent/DE2518986A1/de not_active Ceased
- 1975-04-29 IL IL47196A patent/IL47196A/xx unknown
- 1975-04-30 YU YU1117/75A patent/YU37335B/xx unknown
- 1975-04-30 AT AT332075A patent/AT344167B/de not_active IP Right Cessation
- 1975-04-30 CS CS7500003024A patent/CS183794B2/cs unknown
- 1975-04-30 SU SU7502132902A patent/SU576938A3/ru active
- 1975-05-02 PL PL1975180099A patent/PL99666B1/pl unknown
- 1975-05-02 GB GB18523/75A patent/GB1482238A/en not_active Expired
- 1975-05-02 NL NL7505214A patent/NL7505214A/xx not_active Application Discontinuation
- 1975-05-02 JP JP50052599A patent/JPS6031831B2/ja not_active Expired
- 1975-05-02 DK DK191375A patent/DK191375A/da not_active Application Discontinuation
- 1975-05-02 CH CH564975A patent/CH611289A5/xx not_active IP Right Cessation
- 1975-05-02 NO NO751567A patent/NO147485C/no unknown
- 1975-05-05 FR FR7513942A patent/FR2269340B1/fr not_active Expired
- 1975-06-20 DD DD185801A patent/DD119587A1/xx unknown
-
1981
- 1981-03-18 NO NO810931A patent/NO151177C/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL99666B1 (pl) | 1978-07-31 |
| JPS51125082A (en) | 1976-11-01 |
| AR205818A1 (es) | 1976-06-07 |
| GB1482238A (en) | 1977-08-10 |
| FR2269340A1 (cs) | 1975-11-28 |
| NO810931L (no) | 1975-11-04 |
| FI63568B (fi) | 1983-03-31 |
| ATA332075A (de) | 1977-11-15 |
| NO151177B (no) | 1984-11-19 |
| NO147485B (no) | 1983-01-10 |
| IL47196A (en) | 1978-07-31 |
| AU8072375A (en) | 1976-11-04 |
| CS183794B2 (en) | 1978-07-31 |
| YU111775A (en) | 1983-04-27 |
| AT344167B (de) | 1978-07-10 |
| CH611289A5 (en) | 1979-05-31 |
| DK191375A (da) | 1975-11-04 |
| SU576938A3 (ru) | 1977-10-15 |
| IL47196A0 (en) | 1975-06-25 |
| YU37335B (en) | 1984-08-31 |
| DD119587A1 (cs) | 1976-05-05 |
| FI751272A7 (cs) | 1975-11-04 |
| NO751567L (cs) | 1975-11-04 |
| FR2269340B1 (cs) | 1980-01-25 |
| HU168753B (cs) | 1976-07-28 |
| NO147485C (no) | 1983-04-20 |
| DE2518986A1 (de) | 1975-11-20 |
| NL7505214A (nl) | 1975-11-05 |
| JPS6031831B2 (ja) | 1985-07-24 |
| NO151177C (no) | 1985-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3688827T2 (de) | Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel. | |
| DK2691394T3 (en) | RELATIONSHIPS FOR TREATMENT OF METABOLIC SYNDROME | |
| KR20010013615A (ko) | 4-페닐피페리딘 화합물 | |
| IL29569A (en) | 1,4-dihydropyridine derivatives and their production | |
| US4147780A (en) | α-Amino-phosphonous acids for inhibiting bacteria and yeast | |
| HK1042483A1 (en) | Method for the production of thiazolidin | |
| FR2573075A1 (fr) | Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique | |
| FI63568C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara i 7-staellning substituerade 8-aminometylisoflavonderivat | |
| BE823841A (fr) | Derives de 5-(1-hydroxy-2-amino substitue) alkyl-8-carbostyryle substitue et de 5-(1-hydroxy-2-amino substitue) alkyl-8-(3,4-dihydro) carbostyryle substitue et leur procede de preparation | |
| US4314943A (en) | Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols | |
| CA1240326A (en) | 2-(.omega.-ALKYLAMINOALKYL)-AND 2-(.omega.-DIALKYLAMINOALKYL)- 3-(4-X-BENZYLIDEN)-PHTALIMIDINES | |
| GB2082173A (en) | Isopsoralens | |
| JPH0248567A (ja) | 新規ストロンチウム塩 | |
| JP5486008B2 (ja) | １‐ブチル‐２‐ヒドロキシアラルキルピペラジン誘導体およびその抗鬱剤としての使用 | |
| NO801843L (no) | Nye kinazolinderivater og farmasoeytiske preparater | |
| JPH0692410B2 (ja) | 新規なベンゾフロキノリン誘導体 | |
| FR2460934A1 (fr) | Derives d'isoquinoleine contenant du soufre, procedes pour leur preparation et compositions pharmaceutiques les contenant | |
| JPS5849548B2 (ja) | ピリミジン化合物誘導体の製造法 | |
| DK144822B (da) | Analogifremgangsmaade til fremstilling af hoejredrejende 7-brom-6-chlor-3-(3-(3-hydroxy-2-peperidyl)-acetonyl)-4-3h-quinazolinon eller dets additionssalte med syrer | |
| US4360530A (en) | 5-[p-(Substituted)phenyl]-2,2-dialkyl-4-phenyl-3-oxazoline | |
| CA1205804A (fr) | Procede de preparation de nouvelles imidazoquinoxalines et de leurs sels | |
| KR100556559B1 (ko) | 2-(4-(4-(4,5-디클로로-2-메틸이미다졸-1-일)부틸)-1-피페라지닐)-5-플루오로피리미딘, 이것의 제조 방법 및 이것의치료적 용도 | |
| US2803627A (en) | Therapeutic quinoline compounds | |
| US3433789A (en) | S-benzoyloxymethyl-thiamines | |
| LU82997A1 (fr) | 6-(pyridinyl)-pyridazines,leur preparation et leur utilisation therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: CHINOIN GYOGUSZER ES VEGYESZETI TERMEKEK |